Michael A. Mastrangelo

2.5k total citations
27 papers, 1.8k citations indexed

About

Michael A. Mastrangelo is a scholar working on Physiology, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Michael A. Mastrangelo has authored 27 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Physiology, 9 papers in Molecular Biology and 5 papers in Cellular and Molecular Neuroscience. Recurrent topics in Michael A. Mastrangelo's work include Alzheimer's disease research and treatments (12 papers), Virus-based gene therapy research (5 papers) and Neuroinflammation and Neurodegeneration Mechanisms (5 papers). Michael A. Mastrangelo is often cited by papers focused on Alzheimer's disease research and treatments (12 papers), Virus-based gene therapy research (5 papers) and Neuroinflammation and Neurodegeneration Mechanisms (5 papers). Michael A. Mastrangelo collaborates with scholars based in United States, Hungary and Australia. Michael A. Mastrangelo's co-authors include William J. Bowers, Wade C. Narrow, Howard J. Federoff, Michelle C. Janelsins, Maya Desai, Salvatore Oddo, Frank M. LaFerla, Maria E. Frazer, Deborah A. Ryan and Zheng Gen Jin and has published in prestigious journals such as Nature Communications, Arteriosclerosis Thrombosis and Vascular Biology and American Journal Of Pathology.

In The Last Decade

Michael A. Mastrangelo

27 papers receiving 1.8k citations

Peers

Michael A. Mastrangelo
Sergey Kalinin United States
Carlo Sala Frigerio United Kingdom
Amaia M. Arranz Spain
Émilie Faivre France
Ken-ichiro Fukuchi United States
Vincent Émond Canada
Ding‐I Yang Taiwan
Erik Nutma Netherlands
Nicholas H. Varvel United States
Suizhen Lin United States
Sergey Kalinin United States
Michael A. Mastrangelo
Citations per year, relative to Michael A. Mastrangelo Michael A. Mastrangelo (= 1×) peers Sergey Kalinin

Countries citing papers authored by Michael A. Mastrangelo

Since Specialization
Citations

This map shows the geographic impact of Michael A. Mastrangelo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Mastrangelo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Mastrangelo more than expected).

Fields of papers citing papers by Michael A. Mastrangelo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael A. Mastrangelo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Mastrangelo. The network helps show where Michael A. Mastrangelo may publish in the future.

Co-authorship network of co-authors of Michael A. Mastrangelo

This figure shows the co-authorship network connecting the top 25 collaborators of Michael A. Mastrangelo. A scholar is included among the top collaborators of Michael A. Mastrangelo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael A. Mastrangelo. Michael A. Mastrangelo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mastrangelo, Michael A., Sara Ture, Charles O. Smith, et al.. (2020). The choline transporter Slc44a2 controls platelet activation and thrombosis by regulating mitochondrial function. Nature Communications. 11(1). 3479–3479. 56 indexed citations
2.
Ture, Sara, Michael A. Mastrangelo, Scott J. Cameron, et al.. (2019). Acetylcholine Inhibits Platelet Activation. Journal of Pharmacology and Experimental Therapeutics. 369(2). 182–187. 8 indexed citations
3.
Xu, Suowen, Bin Liu, Meimei Yin, et al.. (2016). A novel TRPV4-specific agonist inhibits monocyte adhesion and atherosclerosis. Oncotarget. 7(25). 37622–37635. 60 indexed citations
4.
Zhu, Qiuyu, Kyung Ae Ko, Sara Ture, et al.. (2016). Novel Thrombotic Function of a Human SNP in STXBP5 Revealed by CRISPR/Cas9 Gene Editing in Mice. Arteriosclerosis Thrombosis and Vascular Biology. 37(2). 264–270. 23 indexed citations
5.
Yin, Meimei, Suowen Xu, Yao Lu, et al.. (2015). Cardiac Gab1 deletion leads to dilated cardiomyopathy associated with mitochondrial damage and cardiomyocyte apoptosis. Cell Death and Differentiation. 23(4). 695–706. 29 indexed citations
6.
Xu, Suowen, Chang Hoon Ha, Weiye Wang, et al.. (2015). PECAM1 regulates flow-mediated Gab1 tyrosine phosphorylation and signaling. Cellular Signalling. 28(3). 117–124. 24 indexed citations
7.
Montgomery, Sara, Wade C. Narrow, Michael A. Mastrangelo, et al.. (2013). Chronic Neuron- and Age-Selective Down-Regulation of TNF Receptor Expression in Triple-Transgenic Alzheimer Disease Mice Leads to Significant Modulation of Amyloid- and Tau-Related Pathologies. American Journal Of Pathology. 182(6). 2285–2297. 47 indexed citations
8.
Montgomery, Sara, Michael A. Mastrangelo, Wade C. Narrow, et al.. (2011). Ablation of TNF-RI/RII Expression in Alzheimer's Disease Mice Leads to an Unexpected Enhancement of Pathology. American Journal Of Pathology. 179(4). 2053–2070. 86 indexed citations
9.
Desai, Maya, et al.. (2010). Early Oligodendrocyte/Myelin Pathology in Alzheimer's Disease Mice Constitutes a Novel Therapeutic Target. American Journal Of Pathology. 177(3). 1422–1435. 171 indexed citations
10.
11.
Mastrangelo, Michael A., et al.. (2009). Extending the transposable payload limit of Sleeping Beauty (SB) using the Herpes Simplex Virus (HSV)/SB amplicon-vector platform. Gene Therapy. 17(3). 424–431. 20 indexed citations
12.
Mastrangelo, Michael A., et al.. (2009). Interferon-γ Differentially Affects Alzheimer’s Disease Pathologies and Induces Neurogenesis in Triple Transgenic-AD Mice. American Journal Of Pathology. 175(5). 2076–2088. 85 indexed citations
13.
Mastrangelo, Michael A., Wade C. Narrow, Maria E. Frazer, et al.. (2009). Generating Differentially Targeted Amyloid-β Specific Intrabodies as a Passive Vaccination Strategy for Alzheimer's Disease. Molecular Therapy. 17(12). 2031–2040. 34 indexed citations
14.
Mastrangelo, Michael A. & William J. Bowers. (2008). Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice. BMC Neuroscience. 9(1). 81–81. 185 indexed citations
15.
16.
Janelsins, Michelle C., Michael A. Mastrangelo, Keigan M. Park, et al.. (2008). Chronic Neuron-Specific Tumor Necrosis Factor-Alpha Expression Enhances the Local Inflammatory Environment Ultimately Leading to Neuronal Death in 3xTg-AD Mice. American Journal Of Pathology. 173(6). 1768–1782. 191 indexed citations
17.
18.
Mastrangelo, Michael A., et al.. (2007). Neuronal Specificity of HSV/Sleeping Beauty Amplicon Transduction In Utero Is Driven Primarily by Tropism and Cell Type Composition. Molecular Therapy. 15(10). 1848–1855. 15 indexed citations
19.
Janelsins, Michelle C., Michael A. Mastrangelo, Salvatore Oddo, et al.. (2005). Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. Journal of Neuroinflammation. 2(1). 23–23. 197 indexed citations
20.
Olschowka, John A., William J. Bowers, Sean D. Hurley, Michael A. Mastrangelo, & Howard J. Federoff. (2003). Helper-free HSV-1 amplicons elicit a markedly less robust innate immune response in the CNS. Molecular Therapy. 7(2). 218–227. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sergey Kalinin Breakdown of academic impact, for papers by Carlo Sala Frigerio Breakdown of academic impact, for papers by Amaia M. Arranz Breakdown of academic impact, for papers by Émilie Faivre Breakdown of academic impact, for papers by Ken-ichiro Fukuchi Breakdown of academic impact, for papers by Vincent Émond Breakdown of academic impact, for papers by Ding‐I Yang Breakdown of academic impact, for papers by Erik Nutma Breakdown of academic impact, for papers by Nicholas H. Varvel Breakdown of academic impact, for papers by Suizhen Lin
Rankless by CCL
2026